• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Study details changes in omicron’s spike protein

Bioengineer by Bioengineer
January 25, 2022
in Biology
Reading Time: 4 mins read
0
Omicron spike protein model
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An international team of scientists has determined the precise structural changes in the spike protein of the omicron variant. Their observations explain how the virus is able to evade antibodies against previous variants and still remain highly infectious.

Omicron spike protein model

Credit: David Veesler Lab

An international team of scientists has determined the precise structural changes in the spike protein of the omicron variant. Their observations explain how the virus is able to evade antibodies against previous variants and still remain highly infectious.

“The findings provide a blueprint that researchers can use to design new countermeasures, whether they be vaccines or therapeutics, against omicron and other coronavirus variants that may emerge,” said David Veesler, investigator with the Howard Hughes Medical Institute and associate professor of biochemistry at the University of Washington School of Medicine in Seattle. He led the research effort with Gyorgy Snell from Vir Biotechnology, Inc. in San Francisco.

The researchers report their findings in the journal Science.

Matthew McCallum, a postdoctoral fellow in Veesler’s lab, and Nadine Czudnochowski, a Vir Biotechnology scientist, were lead authors on the paper.

The omicron variant, which was first identified in November 2021 in South Africa, is causing a surge of infections around the world. In addition to being highly infectious, the variant can evade antibodies against earlier variants leading to breakthrough infections among those who have been vaccinated and those who have been infected previously.

The infectiousness of the virus is thought to be at least in part due to the large number of mutations in the amino acid sequences of the virus’s spike protein. The virus uses the spike protein to latch on to and enter the cells it infects. The omicron spike protein has 37 mutations that distinguish it from the first SARS-CoV-2 isolates in 2020.

Previous research by Veesler and colleagues have shown that antibodies generated by the six most commonly used vaccines, and all but one of monoclonal antibodies currently used to treat infections, have a reduced or abrogated ability to neutralize omicron.

But many of the mutations in the variant affect the structure of the region of the spike protein that is responsible for attaching to and entering cells, a region called the receptor binding domain, and many expected the resulting changes in the receptor binding domain structure might impair the ability of the variant to bind to its target on cells.  This target is  protein called angiotensin converting enzyme-2, or ACE2. However, in their study, Veesler and his colleagues found that the changes had actually increased the ability of the receptor binding domain to bind to ACE2 by 2.4-fold.

To understand how omicron accumulated so many mutations while retaining efficient interactions with the host receptor ACE2, Veesler and his colleagues used cryo-electron microscopic and X-ray crystallographic studies to unveil the 3D organization of the omicron spike protein. The approach allowed them to achieve a resolution of about 3 angstroms. At this resolution, it was possible to discern the shape of individual amino acid building blocks that make up the spike protein. The researchers also determined how the structural changes in the spike protein affected the ability of antibodies effective against previous variants to bind to Omicron.

Using these techniques, the scientists reveal how the mutations changed how the protein interacts with antibodies so that the ability of almost all monoclonal antibodies against it is reduced, while, at the same time the ability of the spike receptor-binding domain to bind ACE2 is enhanced. The overall effect has been to make it possible for the receptor binding domain to evade antibodies targeting it and to bind to ACE2 even more tightly.

The findings demonstrate what a formidable opponent SARS-CoV-2 is, says Veesler.

“This virus has incredible plasticity: It can change a lot and still maintain all the functions it needs to infect and replicate,” he noted. “And it’s almost guaranteed omicron is not the last variant we’re going to see.”

The goal going forward should be to focus on and identify additional regions on the spike protein that cannot be changed without causing the protein to lose function, Veesler said. Because of their importance, these areas tend to remain conserved even as other parts of the protein mutates.

Such conserved regions of viral proteins are therefore likely to remain unchanged in any new variant that might emerge. These regions would make ideal targets for new vaccines and therapeutics that could be effective not only against new variants but new sarbecoviruses, the group of viruses comprising SARS-CoV-2 and SARS-CoV, Veesler said.

The title of the Science paper is “Structural basis of SARS-CoV-2 omicron immune evasion and receptor engagement.”

The research was supported by the National Institute of Health, the National Institute of Allergy and Infectious Disease, the National Institute of General Medical Sciences, the Burroughs Wellcome Fund, Fast Grants, the University of Washington Arnold and Mabel Beckman cryoEM center, the Howard Hughes Medical Institute, the Wellcome Trust  and a Pew Biomedical Scholars Award.

 

News release written by Michael McCarthy



Journal

Science

DOI

10.1126/science.abn8652

Method of Research

Experimental study

Subject of Research

Not applicable

Article Title

Structural basis of SARS-CoV-2 omicron immune evasion and receptor engagement

Article Publication Date

25-Jan-2022

COI Statement

Please see paper for author list. Competing interests: N.C., L.E.R., J.E.D., A.E.P., H.W.V., D.C. and G.S. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. D.C. is currently listed as an inventor on multiple patent applications, which disclose the subject matter described in this manuscript. H.W.V. is a founder and hold shares in PierianDx and Casma Therapeutics. Neither company provided resources. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Share12Tweet8Share2ShareShareShare2

Related Posts

Turtle Meat Trade in Indonesia: Minimal Economic Impact

Turtle Meat Trade in Indonesia: Minimal Economic Impact

September 7, 2025
Winter Waterbirds Adapt to Severe Drought Challenges

Winter Waterbirds Adapt to Severe Drought Challenges

September 7, 2025

Honey Bee Gene Expression Altered by Electric Fields

September 7, 2025

Porcine Placenta Peptide Boosts Hair Health: Studies

September 7, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.